Seegene, Samsung to co-develop molecular diagnostics
ROCKVILLE, Md. & SEOUL, Korea—Seegene and Samsung Medical Center have formed a partnership to co-develop molecular diagnostics (MDx) tests for cancer. The partnership combines Seegene's molecular diagnostic technology leadership and Samsung Medical Center's clinical expertise and disease pathology in order to develop new cancer MDx tests. Seegene will be developing new tests for drug resistance and single nucleotide polymorphism as well, which will be based on its multiplex PCR technology (DPO) and real-time PCR technology (READ). The first tests to be developed will be for colon cancer, pancreatic cancer, non-small cell lung cancer and cholangiocarcinoma. These new MDx tests will allow oncologists to profile a patient's tumor to determine if the patient will likely respond to cancer therapies or chemotherapy, and possibly if the cancer will return or metastasize. Dr. Do Hyun Nam, head of the Samsung Medical Center's Institute for Refractory Cancer Research, says "by collaborating with Seegene, it is anticipated to increase the effectiveness of treatment through early diagnosis."